National Institute on Drug Abuse; Notice of Closed Meetings, 26537-26538 [2021-10153]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 92 / Friday, May 14, 2021 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Eukaryotic
Pathogen Drug Discovery and Resistance.
Date: June 18, 2021.
Time: 10:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Susan Daum, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
Bethesda, MD 20892, (301) 827–7233,
susan.boyle-vavra@nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Clinical Management in General Care
Settings Study Section.
Date: June 21–22, 2021.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lauren Fordyce, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3214,
Bethesda, MD 20892, (301) 435–6998
fordycelm@mail.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group;
Integrative Vascular Physiology and
Pathology Study Section.
Date: June 21–22, 2021.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bukhtiar H. Shah, DVM,
MS, Ph.D., Scientific Review Officer,
Vascular and Hematology, IRG Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4120,
MSC 7802, Bethesda, MD 20892, (301) 806–
7314, shahb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Psychosocial Risks and Behavioral
Medicine Across the Lifespan.
Date: June 21, 2021.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100,
MSC 7808, Bethesda, MD 20892, (301) 594–
3292, niw@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
VerDate Sep<11>2014
19:58 May 13, 2021
Jkt 253001
Dated: May 10, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10157 Filed 5–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, May
26, 2021, 11:00 a.m. to May 26, 2021,
04:00 p.m., National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 which was
published in the Federal Register on
April 20, 2021, 86 FR 20505.
This notice is being amended to
change the meeting end time of the
Center for Scientific Review RFA Panel:
Tobacco Regulatory Science A from 4:00
p.m. to 6:00 p.m. The meeting is closed
to the public.
Dated: May 10, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10221 Filed 5–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Novel Synthetic Nucleic Acid
Technologies.
Date: June 14, 2021.
Time: 1:00 p.m. to 4:00 p.m.
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
26537
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 300, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 300, Bethesda, MD 20817, 301–594–
4280, mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: May 11, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10242 Filed 5–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Contract Review: In Vitro Metabolism and
Non-Clinical ADME Studies (8957).
Date: June 15, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5702, sindhu.kizhakkemadathil@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Contract Review: Development and
Manufacture of Pharmaceutical Products for
the Treatment of Substance Abuse Disorders.
E:\FR\FM\14MYN1.SGM
14MYN1
26538
Federal Register / Vol. 86, No. 92 / Friday, May 14, 2021 / Notices
Date: June 25, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH 301,
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: May 10, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10153 Filed 5–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Sickle Cell Disease
Advisory Committee.
The meeting will be open to the
public. Individuals who plan to attend
and need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Sickle Cell Disease
Advisory Committee.
Date: June 15, 2021.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: Presentations and discussion of
programs.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892, (Virtual Meeting).
Telephone Access: 1–646–828–7666
(Meeting ID: 160 927 6632).
Virtual Access: https://nih.zoomgov.com
(Meeting ID: 161 192 8682).
Contact Person: W. Keith Hoots, MD,
Director, Division of Blood Diseases and
Resources, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Suite 9030,
Bethesda, MD 20892, 301–435–0080,
hootswk@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
VerDate Sep<11>2014
19:58 May 13, 2021
Jkt 253001
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: May 11, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 10, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10154 Filed 5–13–21; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2021–10243 Filed 5–13–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Council of Research Advocates.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: June 16, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: Welcome and Chairwoman’s
Remarks, NCI Updates, Legislative Update,
and Director’s Update.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Amy Williams, NCI, Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive, Building 31,
Room 10A28, Bethesda, MD 20892, (301)
496–9723, williaam@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCRA: https://
deainfo.nci.nih.gov/advisory/ncra/ncra.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; DSPAN F99 Application
Review.
Date: June 14–15, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS, NIH, NSC, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Rockville, MD 20852,
(301) 496–0660, benzingw@mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NINDS DSPAN F99—
Overflow Review.
Date: June 14, 2021.
Time: 3:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS, NIH, NSC, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Rockville, MD 20852,
(301) 496–0660, benzingw@mail.nih.gov.
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
E:\FR\FM\14MYN1.SGM
14MYN1
]]>Agencies
[Federal Register Volume 86, Number 92 (Friday, May 14, 2021)]
[Notices]
[Pages 26537-26538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-10153]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Contract Review: In Vitro Metabolism and Non-
Clinical ADME Studies (8957).
Date: June 15, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 827-5702, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Contract Review: Development and Manufacture of
Pharmaceutical Products for the Treatment of Substance Abuse
Disorders.
[[Page 26538]]
Date: June 25, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH 301, North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: May 10, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-10153 Filed 5-13-21; 8:45 am]
BILLING CODE 4140-01-P
